Tocilizumab/CH12 coupled simulated epitope

A technology of mimetic epitope, CH12, applied in the direction of antibody mimics/scaffolds, receptors/cell surface antigens/cell surface determinants, peptides, etc., can solve the problems of expensive use of antibodies, hypersensitivity reactions, lack of drugs, etc. Achieve the effect of reducing the frequency of drug use, high flexibility and swing, and reducing the cost of use

Active Publication Date: 2016-10-26
杨麟
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although clinical biotherapy of various monoclonal antibodies has advanced the treatment of autoimmune diseases such as rheumatoid arthritis or other refractory diseases, there are still many shortcomings in immunotherapy of monoclonal antibodies: ① Antibody immunotherapy In order to maintain sufficient titers of antibodies, repeated immunizations must be carried out; ②repeated immunizations lead to very expensive use of antibodies; ③side effects of antibody therapy also limit the scope of its application, mainly due to susceptibility to infection and drug hypersensitivity
[0009] The relationship between RA and malignant tumors is relatively clear. Strengthening the understanding and exploration of this aspect is of great significance for diagnosis and treatment. However, there is still a lack of corresponding drugs in diagnosis and treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tocilizumab/CH12 coupled simulated epitope
  • Tocilizumab/CH12 coupled simulated epitope
  • Tocilizumab/CH12 coupled simulated epitope

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0040] The present invention will be further described below in conjunction with specific embodiments, so as to help understand the content of the present invention.

[0041] The preparation and identification process of Tocilizumab / CH12 coupled mimic epitope peptide basically includes:

[0042]1. Synthesis of Tocilizumab / CH12 coupled mimic epitope peptide;

[0043] 2. Tocilizumab / CH12 coupled mimetope peptide immunization animals;

[0044] 3. Purify animal serum to obtain polyclonal antibodies;

[0045] 4. The ability of the purified polyclonal antibody to bind to IL-6R and EGFRvIII expressed by overexpressed cell lines and tumor cell lines was detected by Western blotting;

[0046] 5. Western blotting was used to detect the ability of the purified polyclonal antibody to bind IL-6R and EGFRvIII expressed in rheumatoid arthritis synovial tissue;

[0047] 6. The ability of the purified polyclonal antibody to bind to IL-6R and EGFRvIII expressed by rheumatoid arthritis fibrob...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses tocilizumab/CH12 coupled simulated epitope, having an amino acid sequence that is formed by: connecting C terminal of tocilizumab/CH12 coupled simulated epitope (KTMSAEEFDNWL) and C terminal of CH12 coupled simulated epitope through a linker peptide (GGGSGGS-SGGGSGGG) ('='represents disulfide bond); three polypeptides can be synthesized by using a chemical synthetic process and have linear structure. A dual-specific antibody prepared using the epitope can identify IL-6R and can identify EGFRvIII, thus inhibiting the activity of IL-6 and EFG, producing tocilizumab and enabling add-up of the tocilizumab monoclonal and CH12 and overcoming the problem that there is no need for multiple passive immunity. The simulated epitope of the invention provides novel pharmaceutical means to prevent and treat rheumatoid arthritis and other diseases.

Description

technical field [0001] The invention relates to a mimetic antigen peptide in the technical field of bioengineering, in particular to a Tocilizumab / CH12 coupled mimetic epitope peptide. Background technique [0002] Rheumatoid arthritis (RA) is a chronic, systemic, multidirectional inflammatory autoimmune disease, mainly involving the small joints of the hands and feet, the biggest feature is persistent synovitis, symptoms include joint pain, joint swelling and progressive joint destruction, eventually leading to disability in the patient. [0003] Currently, the drugs used to treat rheumatoid arthritis mainly include hormones, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and emerging biologics. Compared with traditional drugs, biological agents directly act on the main inflammatory factors, which can relieve symptoms more quickly and effectively and inhibit the destruction of joint structures. Currently, biologics for the treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C07K16/46A61K39/00A61K39/395A61P19/02A61P29/00A61P35/00
CPCA61K2039/505C07K14/71C07K14/7155C07K16/2863C07K16/2866C07K2317/31C07K2319/00
Inventor 杨麟
Owner 杨麟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap